Dendreon

PROVENGE

ASP | WAC | AWP at the HCPCS Unit

Manufacturer:

Dendreon

Provenge HCPCS:

Q2043

HCPCS Code Descriptor:

Sipuleucel-t, minimum of 50 million autologous cd54+ cells activated with pap-gm-csf, including leukapheresis and all other preparatory procedures, per infusion

Category:

Q Code

Provenge NDCs:

30237-8900-06

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Package Type:

Bag

Route of Administration:

Intravenous

Provenge CPT Codes:

Some of the most common CPT administration codes for 'buy and bill' drugs can be found at the following link:

Potential NDC Listing Errors:

We have identified listing errors with the following NDCs:

30237-8900-06

About Provenge:

PROVENGE is an Oncology drug manufactured by Dendreon and administered via the Intravenous route of administration. The Q Code: Q2043 is aligned to the drug PROVENGE.

ACCESS PRICING AND MORE BY REGISTERING

Q2043 Added Date:

July 1, 2011

Q2043 Effective Date:

July 1, 2011

Q2043 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Provenge billing and coding information.
Provenge patient assistance information can be found through Dendreon ON Call at the URL: https://www.dendreononcall.com/
PROVENGE prescribing information can be found at the link below:
Information regarding PROVENGE’s side effects can be found at MedlinePlus